Eagle Pharmaceuticals, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 8 rows in 2023. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2023-12-21: Reporting owner Graves Michael; Form 4; Security Employee Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2023-10-27: Reporting owner Graves Michael; Form 4; Security Stock Option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2023-03-07: Reporting owner RATOFF STEVEN B; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2023-03-07: Reporting owner Graves Michael; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2023-12-21 | Graves Michael Director, Officer (Interim Executive Chair & PEO) | 4 | Employee Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +293,000 293,000 owned after | $5.01 exercise price | 2023-12-22 | |
| 2023-10-27 | Graves Michael Director | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −9,360 0 owned after | $4.94 exercise price | 2023-10-31 | |
| 2023-03-07 | RATOFF STEVEN B Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +16,253 16,253 owned after | $26.00 exercise price | 2023-03-09 | |
| 2023-03-07 | Graves Michael Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +16,253 16,253 owned after | $26.00 exercise price | 2023-03-09 | |
| 2023-03-07 | Simpson Jennifer K. Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +16,253 16,253 owned after | $26.00 exercise price | 2023-03-09 | |
| 2023-03-07 | Glenning Robert Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +16,253 16,253 owned after | $26.00 exercise price | 2023-03-09 | |
| 2023-03-07 | Edlin Richard A. Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +16,253 16,253 owned after | $26.00 exercise price | 2023-03-09 | |
| 2023-03-07 | BORIO LUCIANA Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +16,253 16,253 owned after | $26.00 exercise price | 2023-03-09 |